TY - BOOK PY - 2014 DA - 2014// TI - 90-90-90. An ambitious treatment target to help end the AIDS epidemic ID - ref1 ER - TY - JOUR AU - Gourlay, A. AU - Noori, T. AU - Pharris, A. AU - Axelsson, M. AU - Costagliola, D. AU - Cowan, S. PY - 2017 DA - 2017// TI - The human immunodeficiency virus continuum of Care in European Union Countries in 2013: data and challenges JO - Clin Infect Dis VL - 64 UR - https://doi.org/10.1093/cid/cix212 DO - 10.1093/cid/cix212 ID - Gourlay2017 ER - TY - STD TI - UNAIDS. ENDING AIDS-Progress towards the 90–90-90 targets. http://www.unaids.org/sites/default/files/media_asset/Global_AIDS_update_2017_en.pdf. Accessed 18 Jan 2019. UR - http://www.unaids.org/sites/default/files/media_asset/Global_AIDS_update_2017_en.pdf ID - ref3 ER - TY - STD TI - UNAIDS. Miles to go-closing gaps, breaking barriers, righting injustices. https://www.unaids.org/sites/default/files/media_asset/miles-to-go_en.pdf. Accessed 16 Jan 2019. UR - https://www.unaids.org/sites/default/files/media_asset/miles-to-go_en.pdf ID - ref4 ER - TY - JOUR AU - Gupta, R. K. AU - Gregson, J. AU - Parkin, N. AU - Haile-Selassie, H. AU - Tanuri, A. AU - Andrade Forero, L. PY - 2018 DA - 2018// TI - HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis JO - Lancet Infect Dis VL - 18 UR - https://doi.org/10.1016/S1473-3099(17)30702-8 DO - 10.1016/S1473-3099(17)30702-8 ID - Gupta2018 ER - TY - STD TI - WHO. HIV drug resistance report 2017. http://www.who.int/hiv/topics/drugresistance/en. Accessed 22 Jan 2019. UR - http://www.who.int/hiv/topics/drugresistance/en ID - ref6 ER - TY - STD TI - WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. http://www.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1. Accessed 02 Feb 2019. UR - http://www.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1 ID - ref7 ER - TY - JOUR AU - Boender, T. S. AU - Hoenderboom, B. M. AU - Sigaloff, K. C. AU - Hamers, R. L. AU - Wellington, M. AU - Shamu, T. PY - 2015 DA - 2015// TI - Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa JO - Clin Infect Dis VL - 61 ID - Boender2015 ER - TY - STD TI - WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 2016.http://www.who.int/hiv/pub/arv/arv-2016/en. Accessed 15 Feb 2019. UR - http://www.who.int/hiv/pub/arv/arv-2016/en ID - ref9 ER - TY - JOUR AU - Phillips, A. N. AU - Stover, J. AU - Cambiano, V. AU - Nakagawa, F. AU - Jordan, M. R. AU - Pillay, D. PY - 2017 DA - 2017// TI - Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in sub–Saharan Africa JO - J Infect Dis VL - 215 UR - https://doi.org/10.1093/infdis/jix089 DO - 10.1093/infdis/jix089 ID - Phillips2017 ER - TY - JOUR AU - Brenner, B. AU - Turner, D. AU - Oliveira, M. AU - Moisi, D. AU - Detorio, M. AU - Carobene, M. PY - 2003 DA - 2003// TI - A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors JO - AIDS. VL - 17 UR - https://doi.org/10.1097/00002030-200301030-00001 DO - 10.1097/00002030-200301030-00001 ID - Brenner2003 ER - TY - STD TI - Ndashimye E, Avino M, Kyeyune F, et al. Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda. AIDS Res Hum Retroviruses. 2018;34(5):404–14. ID - ref12 ER - TY - JOUR AU - Steegen, K. AU - Bronze, M. AU - Papathanasopoulos, M. A. AU - Zyl, G. AU - Goedhals, D. AU - Vuuren, C. PY - 2016 DA - 2016// TI - Prevalence of antiretroviral drug resistance in patients who are not responding to protease inhibitor-based treatment: results from the first National Survey in South Africa JO - J Infect Dis VL - 214 UR - https://doi.org/10.1093/infdis/jiw491 DO - 10.1093/infdis/jiw491 ID - Steegen2016 ER - TY - JOUR AU - Rawizza, H. E. AU - Chaplin, B. AU - Meloni, S. T. AU - Darin, K. M. AU - Olaitan, O. AU - Scarsi, K. K. PY - 2013 DA - 2013// TI - Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0073582 DO - 10.1371/journal.pone.0073582 ID - Rawizza2013 ER - TY - JOUR PY - 2016 DA - 2016// JO - Lancet Infect Dis VL - 16 UR - https://doi.org/10.1016/S1473-3099(15)00536-8 DO - 10.1016/S1473-3099(15)00536-8 ID - ref15 ER - TY - JOUR AU - Mannheimer, S. AU - Friedland, G. AU - Matts, J. AU - Child, C. AU - Chesney, M. PY - 2002 DA - 2002// TI - The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials JO - Clin Infect Dis VL - 34 UR - https://doi.org/10.1086/339074 DO - 10.1086/339074 ID - Mannheimer2002 ER - TY - JOUR AU - Garcia de Olalla, P. AU - Knobel, H. AU - Carmona, A. AU - Guelar, A. AU - Lopez-Colomes, J. L. AU - Cayla, J. A. PY - 2002 DA - 2002// TI - Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients JO - J Acquir Immune Defic Syndr VL - 30 UR - https://doi.org/10.1097/00042560-200205010-00014 DO - 10.1097/00042560-200205010-00014 ID - Garcia de Olalla2002 ER - TY - JOUR AU - Berg, K. M. AU - Cooperman, N. A. AU - Newville, H. AU - Arnsten, J. H. PY - 2009 DA - 2009// TI - Self-efficacy and depression as mediators of the relationship between pain and antiretroviral adherence JO - AIDS Care VL - 21 UR - https://doi.org/10.1080/09540120802001697 DO - 10.1080/09540120802001697 ID - Berg2009 ER - TY - JOUR AU - Mark, D. AU - Armstrong, A. AU - Andrade, C. AU - Penazzato, M. AU - Hatane, L. AU - Taing, L. PY - 2017 DA - 2017// TI - HIV treatment and care services for adolescents: a situational analysis of 218 facilities in 23 sub-Saharan African countries JO - J Int AIDS Soc VL - 20 ID - Mark2017 ER - TY - JOUR AU - Mills, E. J. AU - Lester, R. AU - Thorlund, K. AU - Lorenzi, M. AU - Muldoon, K. AU - Kanters, S. PY - 2014 DA - 2014// TI - Interventions to promote adherence to antiretroviral therapy in Africa: a network meta-analysis JO - Lancet HIV VL - 1 UR - https://doi.org/10.1016/S2352-3018(14)00003-4 DO - 10.1016/S2352-3018(14)00003-4 ID - Mills2014 ER - TY - JOUR AU - Orkin, C. AU - DeJesus, E. AU - Khanlou, H. AU - Stoehr, A. AU - Supparatpinyo, K. AU - Lathouwers, E. PY - 2013 DA - 2013// TI - Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial JO - HIV Med VL - 14 UR - https://doi.org/10.1111/j.1468-1293.2012.01060.x DO - 10.1111/j.1468-1293.2012.01060.x ID - Orkin2013 ER - TY - JOUR AU - LaFleur, J. AU - Bress, A. P. AU - Rosenblatt, L. AU - Crook, J. AU - Sax, P. E. AU - Myers, J. PY - 2017 DA - 2017// TI - Cardiovascular outcomes among HIV-infected veterans receiving atazanavir JO - AIDS. VL - 31 UR - https://doi.org/10.1097/QAD.0000000000001594 DO - 10.1097/QAD.0000000000001594 ID - LaFleur2017 ER - TY - JOUR AU - Boerma, R. S. AU - Sigaloff, K. C. AU - Akanmu, A. S. AU - Inzaule, S. AU - Boele van Hensbroek, M. AU - Rinke de Wit, T. F. PY - 2017 DA - 2017// TI - Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis JO - J Antimicrob Chemother VL - 72 UR - https://doi.org/10.1093/jac/dkw463 DO - 10.1093/jac/dkw463 ID - Boerma2017 ER - TY - JOUR AU - Cohen, C. J. AU - Andrade-Villanueva, J. AU - Clotet, B. AU - Fourie, J. AU - Johnson, M. A. AU - Ruxrungtham, K. PY - 2011 DA - 2011// TI - Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial JO - Lancet. VL - 378 UR - https://doi.org/10.1016/S0140-6736(11)60983-5 DO - 10.1016/S0140-6736(11)60983-5 ID - Cohen2011 ER - TY - JOUR AU - Baxter, J. D. AU - Dunn, D. AU - White, E. AU - Sharma, S. AU - Geretti, A. M. AU - Kozal, M. J. PY - 2015 DA - 2015// TI - Global HIV-1 transmitted drug resistance in the INSIGHT strategic timing of AntiRetroviral treatment (START) trial JO - HIV Med. VL - 16 UR - https://doi.org/10.1111/hiv.12236 DO - 10.1111/hiv.12236 ID - Baxter2015 ER - TY - JOUR AU - Bansi, L. AU - Geretti, A. M. AU - Dunn, D. AU - Hill, T. AU - Green, H. AU - Fearnhill, E. PY - 2010 DA - 2010// TI - Impact of transmitted drug-resistance on treatment selection and outcome of first-line highly active antiretroviral therapy (HAART) JO - J Acquir Immune Defic Syndr VL - 53 ID - Bansi2010 ER - TY - JOUR AU - Phanuphak, P. AU - Sirivichayakul, S. AU - Jiamsakul, A. AU - Sungkanuparph, S. AU - Kumarasamy, N. AU - Lee, M. P. PY - 2014 DA - 2014// TI - Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia JO - J Acquir Immune Defic Syndr VL - 66 UR - https://doi.org/10.1097/QAI.0000000000000108 DO - 10.1097/QAI.0000000000000108 ID - Phanuphak2014 ER - TY - JOUR AU - Ndembi, N. AU - Lyagoba, F. AU - Nanteza, B. AU - Kushemererwa, G. AU - Serwanga, J. AU - Katongole-Mbidde, E. PY - 2008 DA - 2008// TI - Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe JO - Uganda AIDS Res Hum Retroviruses VL - 24 UR - https://doi.org/10.1089/aid.2007.0317 DO - 10.1089/aid.2007.0317 ID - Ndembi2008 ER - TY - JOUR AU - Ndembi, N. AU - Hamers, R. L. AU - Sigaloff, K. C. AU - Lyagoba, F. AU - Magambo, B. AU - Nanteza, B. PY - 2011 DA - 2011// TI - Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala JO - Aids. VL - 25 UR - https://doi.org/10.1097/QAD.0b013e328346260f DO - 10.1097/QAD.0b013e328346260f ID - Ndembi2011 ER - TY - JOUR AU - Frentz, D. AU - Boucher, C. A. AU - Vijver, D. A. PY - 2012 DA - 2012// TI - Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world JO - AIDS Rev VL - 14 ID - Frentz2012 ER - TY - JOUR AU - Derdelinckx, I. AU - Laethem, K. AU - Maes, B. AU - Schrooten, Y. AU - Wit, S. AU - Florence, E. PY - 2004 DA - 2004// TI - Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response JO - J Acquir Immune Defic Syndr VL - 37 UR - https://doi.org/10.1097/00126334-200412150-00022 DO - 10.1097/00126334-200412150-00022 ID - Derdelinckx2004 ER - TY - JOUR AU - Hofstra, L. M. AU - Sauvageot, N. AU - Albert, J. AU - Alexiev, I. AU - Garcia, F. AU - Struck, D. PY - 2016 DA - 2016// TI - Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe JO - Clin Infect Dis VL - 62 UR - https://doi.org/10.1093/cid/civ963 DO - 10.1093/cid/civ963 ID - Hofstra2016 ER - TY - JOUR AU - Kyeyune, F. AU - Gibson, R. M. AU - Nankya, I. AU - Venner, C. AU - Metha, S. AU - Akao, J. PY - 2016 DA - 2016// TI - Low-frequency drug resistance in HIV-infected Ugandans on antiretroviral treatment is associated with regimen failure JO - Antimicrob Agents Chemother VL - 60 UR - https://doi.org/10.1128/AAC.00038-16 DO - 10.1128/AAC.00038-16 ID - Kyeyune2016 ER - TY - STD TI - WHO. The availability and use of diagnostics for HIV: a 2012/2013 WHO survey of low-and middle-income countries. http://www.who.int/iris/bitstream/10665/147213/1/9789241507905_eng.pdf?ua=1. Accessed 14 Jan 2019. UR - http://www.who.int/iris/bitstream/10665/147213/1/9789241507905_eng.pdf?ua=1 ID - ref34 ER - TY - JOUR AU - Kityo, C. AU - Boerma, R. S. AU - Sigaloff, K. C. E. AU - Kaudha, E. AU - Calis, J. C. J. AU - Musiime, V. PY - 2017 DA - 2017// TI - Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children JO - J Antimicrob Chemother VL - 72 UR - https://doi.org/10.1093/jac/dkx188 DO - 10.1093/jac/dkx188 ID - Kityo2017 ER - TY - STD TI - Médecins Sans Frontières. Untangling the web of antiretroviral price reductions 2016. 18th Edition. https://www.msfaccess.org/untangling-web-antiretroviral-price-reductions-18th-edition. Accessed 13 Jan 2019. UR - https://www.msfaccess.org/untangling-web-antiretroviral-price-reductions-18th-edition ID - ref36 ER - TY - STD TI - Hill A, et al. Generic treatments for HIV, HBV, HCV, TB could be mass produced for <$90 per patient. 9th international AIDS society conference on HIV science, Paris, abstract TUAD0104, 2017. ID - ref37 ER - TY - STD TI - Godfrey C, Thigpen MC, Crawford KW, et al. Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation. J Infect Dis. 2017;216(suppl_9):S798–S800. ID - ref38 ER - TY - STD TI - UNITAID. Kenya to introduce better treatment for people living with HIV 2017. http://www.unitaid.eu/news-blog/kenya-introduce-better-treatment-people-living-hiv/#en. Accessed 12 Jan 2019. UR - http://www.unitaid.eu/news-blog/kenya-introduce-better-treatment-people-living-hiv/#en ID - ref39 ER - TY - JOUR AU - Zash, R. AU - Jacobson, D. L. AU - Diseko, M. AU - Mayondi, G. AU - Mmalane, M. AU - Essex, M. PY - 2018 DA - 2018// TI - Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study JO - Lancet Glob Health VL - 6 UR - https://doi.org/10.1016/S2214-109X(18)30218-3 DO - 10.1016/S2214-109X(18)30218-3 ID - Zash2018 ER - TY - JOUR AU - Zash, R. AU - Makhema, J. AU - Shapiro, R. L. PY - 2018 DA - 2018// TI - Neural-tube defects with Dolutegravir treatment from the time of conception JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMc1807653 DO - 10.1056/NEJMc1807653 ID - Zash2018 ER - TY - STD TI - WHO. Potential safety issue affecting women living with HIV using dolutegravir at the time of conception .https://www.who.int/medicines/publications/drugalerts/Statement_on_DTG_18May_2018final.pdf?ua=1. Accessed 12 Jan 2019. UR - https://www.who.int/medicines/publications/drugalerts/Statement_on_DTG_18May_2018final.pdf?ua=1 ID - ref42 ER - TY - JOUR AU - Martinez de Tejada, B. PY - 2019 DA - 2019// TI - Birth defects after exposure to Efavirenz-based antiretroviral therapy at conception/first trimester of pregnancy: a multicohort analysis JO - J Acquir Immune Defic Syndr VL - 80 UR - https://doi.org/10.1097/QAI.0000000000001922 DO - 10.1097/QAI.0000000000001922 ID - Martinez de Tejada2019 ER - TY - JOUR AU - Norwood, J. AU - Turner, M. AU - Bofill, C. AU - Rebeiro, P. AU - Shepherd, B. AU - Bebawy, S. PY - 2017 DA - 2017// TI - Brief report: weight gain in persons with HIV switched from Efavirenz-based to integrase Strand transfer inhibitor-based regimens JO - J Acquir Immune Defic Syndr VL - 76 UR - https://doi.org/10.1097/QAI.0000000000001525 DO - 10.1097/QAI.0000000000001525 ID - Norwood2017 ER - TY - JOUR AU - Fenton, C. AU - Perry, C. M. PY - 2007 DA - 2007// TI - Darunavir: in the treatment of HIV-1 infection JO - Drugs. VL - 67 UR - https://doi.org/10.2165/00003495-200767180-00010 DO - 10.2165/00003495-200767180-00010 ID - Fenton2007 ER - TY - JOUR AU - Clotet, B. AU - Bellos, N. AU - Molina, J. M. AU - Cooper, D. AU - Goffard, J. C. AU - Lazzarin, A. PY - 2007 DA - 2007// TI - Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials JO - Lancet. VL - 369 UR - https://doi.org/10.1016/S0140-6736(07)60497-8 DO - 10.1016/S0140-6736(07)60497-8 ID - Clotet2007 ER - TY - JOUR AU - Poveda, E. AU - Mendoza, C. AU - Parkin, N. AU - Choe, S. AU - Garcia-Gasco, P. AU - Corral, A. PY - 2008 DA - 2008// TI - Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes JO - AIDS. VL - 22 UR - https://doi.org/10.1097/QAD.0b013e3282f51eb9 DO - 10.1097/QAD.0b013e3282f51eb9 ID - Poveda2008 ER - TY - JOUR AU - Andries, K. AU - Azijn, H. AU - Thielemans, T. AU - Ludovici, D. AU - Kukla, M. AU - Heeres, J. PY - 2004 DA - 2004// TI - TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1 JO - Antimicrob Agents Chemother VL - 48 UR - https://doi.org/10.1128/AAC.48.12.4680-4686.2004 DO - 10.1128/AAC.48.12.4680-4686.2004 ID - Andries2004 ER - TY - JOUR AU - Llibre, J. M. AU - Santos, J. R. AU - Puig, T. AU - Molto, J. AU - Ruiz, L. AU - Paredes, R. PY - 2008 DA - 2008// TI - Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz JO - J Antimicrob Chemother VL - 62 UR - https://doi.org/10.1093/jac/dkn297 DO - 10.1093/jac/dkn297 ID - Llibre2008 ER - TY - JOUR AU - Feng, M. AU - Sachs, N. A. AU - Xu, M. AU - Grobler, J. AU - Blair, W. AU - Hazuda, D. J. PY - 2016 DA - 2016// TI - Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations JO - Antimicrob Agents Chemother VL - 60 UR - https://doi.org/10.1128/AAC.02650-15 DO - 10.1128/AAC.02650-15 ID - Feng2016 ER - TY - STD TI - Squires K et al. Fixed dose combination of doravirine/lamivudine/TDF is non-inferior to efavirenz/emitricabine/TDF in treatment-naive adults with HIV-1 infection:week 48 results of the phase 3 DRVE-AHEAD study. 9th international AIDS society conference on HIV science, Paris, abstract TUAB0104LB, 2017. ID - ref51 ER - TY - BOOK AU - Randovitz, R. PY - 2017 DA - 2017// TI - Safety, tolerability and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-infected women and men: HPTN 077. 9th international AIDS society coneference on HIV science, Paris, abstract TUAC0106LB ID - Randovitz2017 ER - TY - BOOK AU - Gallant, J. PY - 2017 DA - 2017// TI - A phase 3 randomised controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naive adults at week 48. 9th international AIDS society conference on HIV science, Paris, abstract MOAB0105LB ID - Gallant2017 ER - TY - STD TI - Matthews RP, et al. Single doses as low as 0.5 mg of the novel NRTTI MK-8591 suppress HIV for at least seven days. 9th International AIDS Society Conference on HIV Science, Paris, abstract TUPDB0202LB, 2017. ID - ref54 ER - TY - STD TI - WHO. Global action plan on HIV drug resistance 2017–2021. https://apps.who.int/iris/bitstream/handle/10665/255883/9789241512848-eng.pdf?sequence=1. Accessed 14 Jan 2019. UR - https://apps.who.int/iris/bitstream/handle/10665/255883/9789241512848-eng.pdf?sequence=1 ID - ref55 ER - TY - JOUR AU - Salou, M. AU - Butel, C. AU - Konou, A. A. AU - Ekouevi, D. K. AU - Vidal, N. AU - Dossim, S. PY - 2016 DA - 2016// TI - High rates of drug resistance among newly diagnosed HIV-infected children in the National Prevention of mother-to-child transmission program in Togo JO - Pediatr Infect Dis J VL - 35 UR - https://doi.org/10.1097/INF.0000000000001203 DO - 10.1097/INF.0000000000001203 ID - Salou2016 ER - TY - JOUR AU - Poppe, L. K. AU - Chunda-Liyoka, C. AU - Kwon, E. H. AU - Gondwe, C. AU - West, J. T. AU - Kankasa, C. PY - 2017 DA - 2017// TI - HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens JO - AIDS. VL - 31 UR - https://doi.org/10.1097/QAD.0000000000001569 DO - 10.1097/QAD.0000000000001569 ID - Poppe2017 ER - TY - JOUR AU - Jordan, M. R. AU - Penazzato, M. AU - Cournil, A. AU - Vubil, A. AU - Jani, I. AU - Hunt, G. PY - 2017 DA - 2017// TI - Human immunodeficiency virus (HIV) drug resistance in African infants and young children newly diagnosed with HIV: a multicountry analysis JO - Clin Infect Dis VL - 65 UR - https://doi.org/10.1093/cid/cix698 DO - 10.1093/cid/cix698 ID - Jordan2017 ER - TY - JOUR AU - Kanthula, R. AU - Rossouw, T. M. AU - Feucht, U. D. AU - Dyk, G. AU - Beck, I. A. AU - Silverman, R. PY - 2017 DA - 2017// TI - Persistence of HIV drug resistance among south African children given nevirapine to prevent mother-to-child-transmission JO - AIDS. VL - 31 UR - https://doi.org/10.1097/QAD.0000000000001446 DO - 10.1097/QAD.0000000000001446 ID - Kanthula2017 ER - TY - JOUR AU - Kuhn, L. AU - Hunt, G. AU - Technau, K. G. AU - Coovadia, A. AU - Ledwaba, J. AU - Pickerill, S. PY - 2014 DA - 2014// TI - Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis JO - AIDS. VL - 28 UR - https://doi.org/10.1097/QAD.0000000000000261 DO - 10.1097/QAD.0000000000000261 ID - Kuhn2014 ER - TY - JOUR AU - Kityo, C. AU - Sigaloff, K. C. AU - Sonia Boender, T. AU - Kaudha, E. AU - Kayiwa, J. AU - Musiime, V. PY - 2016 DA - 2016// TI - HIV drug resistance among children initiating first-line antiretroviral treatment in Uganda JO - AIDS Res Hum Retrovir VL - 32 UR - https://doi.org/10.1089/aid.2015.0215 DO - 10.1089/aid.2015.0215 ID - Kityo2016 ER - TY - JOUR AU - Chimukangara, B. AU - Lessells, R. J. AU - Rhee, S. -. Y. AU - Giandhari, J. AU - Kharsany, A. B. M. AU - Naidoo, K. PY - 2019 DA - 2019// TI - Trends in pretreatment HIV-1 drug resistance in antiretroviral therapy naive adults in South Africa, 2000-2016: a pooled sequence analysis JO - Lancet. VL - 9 ID - Chimukangara2019 ER - TY - JOUR AU - Afonso, J. M. AU - Bello, G. AU - Guimaraes, M. L. AU - Sojka, M. AU - Morgado, M. G. PY - 2012 DA - 2012// TI - HIV-1 genetic diversity and transmitted drug resistance mutations among patients from the north, central and south regions of Angola JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0042996 DO - 10.1371/journal.pone.0042996 ID - Afonso2012 ER - TY - JOUR AU - Rowley, C. F. AU - MacLeod, I. J. AU - Maruapula, D. AU - Lekoko, B. AU - Gaseitsiwe, S. AU - Mine, M. PY - 2016 DA - 2016// TI - Sharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillance JO - J Antimicrob Chemother VL - 71 UR - https://doi.org/10.1093/jac/dkv500 DO - 10.1093/jac/dkv500 ID - Rowley2016 ER - TY - JOUR AU - Perez, L. AU - Kouri, V. AU - Aleman, Y. AU - Abrahantes, Y. AU - Correa, C. AU - Aragones, C. PY - 2013 DA - 2013// TI - Antiretroviral drug resistance in HIV-1 therapy-naive patients in Cuba JO - Infect Genet Evol VL - 16 UR - https://doi.org/10.1016/j.meegid.2013.02.002 DO - 10.1016/j.meegid.2013.02.002 ID - Perez2013 ER - TY - JOUR AU - Avila-Rios, S. AU - Garcia-Morales, C. AU - Matias-Florentino, M. AU - Romero-Mora, K. A. AU - Tapia-Trejo, D. AU - Quiroz-Morales, V. S. PY - 2016 DA - 2016// TI - Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey JO - Lancet HIV. VL - 3 UR - https://doi.org/10.1016/S2352-3018(16)30119-9 DO - 10.1016/S2352-3018(16)30119-9 ID - Avila-Rios2016 ER - TY - JOUR AU - Lavu, E. AU - Kave, E. AU - Mosoro, E. AU - Markby, J. AU - Aleksic, E. AU - Gare, J. PY - 2017 DA - 2017// TI - High levels of transmitted HIV drug resistance in a study in Papua New Guinea JO - PLoS One VL - 12 UR - https://doi.org/10.1371/journal.pone.0170265 DO - 10.1371/journal.pone.0170265 ID - Lavu2017 ER - TY - STD TI - WHO. HIV drug resistance surveillance guidance-2015 update. https://apps.who.int/iris/bitstream/handle/10665/204471/9789241510097_eng.pdf?sequence=1. Accessed 2 Jan 2019. UR - https://apps.who.int/iris/bitstream/handle/10665/204471/9789241510097_eng.pdf?sequence=1 ID - ref68 ER -